Clinical ResearchAntithrombotic TherapyA Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions: Results From the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial
Antithrombotic Therapy
Under an Elsevier user license
open archive
Key Words
cilostazol
coronary artery disease
triple antiplatelet therapy
zotarolimus-eluting stent
Abbreviations and Acronyms
BMS
bare-metal stent(s)
CI
confidence interval
DES
drug-eluting stent(s)
EEM
external elastic membrane
IVUS
intravascular ultrasound
MI
myocardial infarction
QCA
quantitative coronary angiography
TLR
target lesion revascularization
TVR
target vessel revascularization
ZES
zotarolimus-eluting stent(s)
Cited by (0)
DECLARE-LONG II was supported by Korea Otsuka Pharmaceutical Co., Ltd (funding source), and the Cardiovascular Research Foundation, Seoul, Korea. Korea Otsuka Pharmaceutical Co., Ltd., had no role in the study design, data collection, data analysis, or data interpretation; had no access to the clinical trial database; and did not have the opportunity to review or comment on the report.
For full author disclosures, please see the end of this paper.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.